SPY411.49+2.97 0.73%
DIA337.86+2.73 0.81%
IXIC13,900.19+70.88 0.51%

Kindred Biosciences Believes Cash, Cash Equivalents and Investments, Revenues Will Be Sufficient to Fund Oper Plan Through Early 2023, Ex-Drawdown of $30 M From Debt Facility

Kindred Biosciences Believes Cash, Cash Equivalents and Investments, Revenues Will Be Sufficient to Fund Oper Plan Through Early 2023, Ex-Drawdown of $30 M From Debt Facility

· 03/16/2021 16:05

Please log in to view news